Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
Keros Therapeutics Inc KROS had a dream debut, with the company pricing the shares at the high-end of the estimated range and the shares closing the debut session about 26% higher than the IPO price.
This upcoming week is likely to continue to see more pre-announcements and disclosures regarding how the COVID-19 pandemic is impacting operations, cash position, financials and clinical trials.
Conferences
Needham Virtual Healthcare Conference: April 14-15
PDUFA Date
The FDA is set to rule Saturday on Urogen Pharma Ltd's URGN NDA for UGN-101 (mitomycin gel), which is being evaluated for the treatment of low-grade, upper tract urothelial cancer.
Clinical Readouts
Vir Biotechnology Inc VIR on Wednesday will present at a Key Opinion leader call, an update on its Phase 1/2 hepatitis B virus clinical trial with small interfering ribonucleic acid VIR-2218. Vir had licensed the investigational asset from Alnylam Pharmaceuticals, Inc. ALNY.
See Also: Novavax Identifies COVID-19 Vaccine Candidate, Human Testing To Begin In Mid-May
Mid-April Schedule
Ascendis Pharma A/S ASND: top-line data from PaTH Forward Phase 2 study of TransCon hGH in treating hypoparathryroidism
Gilead Sciences, Inc. GILD could release results from the Phase 3 China studies of remdesivir for the treatment of COVID-19 (sell-side estimate a mid-April release)
Early Q2 Schedule
Axsome Therapeutics Inc AXSM: top-line data from the Phase 2/3 study dubbed ADVANCE-1 that is evaluating AXS-05 for treating agitation in patients with Alzheimer's disease
SCYNEXIS Inc SCYX: top-line data from Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis
Ovid Therapeutics Inc OVID: data from the signal-finding Phase 2 ROCKET trial in Fragile X syndrome along with SKYROCKET, its non-interventional trial in Fragile X syndrome.
Iterum Therapeutics PLC ITRM: top-line results from the Phase 3 study of sulopenem in complicated urinary tract infection and uncomplicated urinary tract infection
Earnings
Monday
- Amarin Corporation plc AMRN (after the close)
Tuesday
- Johnson & Johnson JNJ (before the market open)
Thursday
- Abbott Laboratories ABT (before the market open)
- Intuitive Surgical, Inc. ISRG (after the close)
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.